Stock 04K KNIGHT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Knight Therapeutics Inc. Deutsche Boerse AG

Equities

04K

CA4990531069

Market Closed - Deutsche Boerse AG
Other stock markets
 07:02:46 28/06/2024 BST 		5-day change 1st Jan Change
3.76 EUR +0.53% Intraday chart for Knight Therapeutics Inc. +2.17% +6.82%
05-09 Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1 MT
05-09 Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Knight Therapeutics Up Near 3% After Announcing Supply and Distribution Agreement For ADHD Medication; Despite Mixed Q1
MT
Transcript : Knight Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Knight Therapeutics Brief: Q1 Net loss was $4.546 Million; Revenues were $86.604 Million
MT
Knight Therapeutics Brief: Entering into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM In Canada and Latin America
MT
Knight Therapeutics Reports First Quarter 2024 Results
GL
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America
GL
Knight Therapeutics Inc. Reconfirms Earnings Guidance for the Year 2024
CI
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for Jornay Pm® for Canada and Latin America
CI
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
GL
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
AQ
Knight to Present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City
GL
Notice of Knight Therapeutics' First Quarter 2024 Results Conference Call
GL
Knight to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
GL
Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity
GL
Knight Therapeutics Price Target Raised to $7 at RBC
MT
Knight Therapeutics Reports Fourth Quarter Results
MT
Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2024
CI
Transcript : Knight Therapeutics Inc., Q4 2023 Earnings Call, Mar 21, 2024
Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GUD Stock
  4. 04K Stock
  5. News Knight Therapeutics Inc.